Badanie Zimmer Continuum Metal na polietylenie (MoP) po wprowadzeniu do obrotu (PMCF)
Prospektywne kliniczne badanie kontrolne po wprowadzeniu na rynek metalu kontinuum na polietylenowym układzie panewkowym
This is a prospective, multi-center, non-randomized, non-controlled study designed to obtain survival and outcome data on the Continuum Metal on Polyethylene Acetabular System when used in primary total hip arthroplasty.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
The safety and performance of the Continuum Metal on Polyethylene Acetabular System will be confirmed by the assessment of survival and outcome data. Assessments will include standard scoring systems, radiographs and adverse event records. Data will be used to monitor pain, mobility, and survivorship of the Continuum Metal on Polyethylene Acetabular system in primary total hip arthroplasty. Metal ion (cobalt, chromium and titanium) and renal function (BUN, Creatinine and GFR) levels will be analyzed for a subset of the enrolled study subjects.
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
California
-
Fremont, California, Stany Zjednoczone, 94538
- Sah Orthopaedic Associates
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone, 80204
- Denver Health Medical Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Patients from surgeons medical practice who are candidates for primary hip arthroplasty.
The study population will be comprised of 300 males and females who require primary total hip arthroplasty. Subjects will be enrolled at up to 7 clinical sites. Subjects must be geographically accessible throughout the study and be willing and able to attend required follow-up appointments. Candidates who express interest in study participation will be offered informed consent, and eligibility will be determined based upon the inclusion/exclusion criteria.
Opis
Inclusion Criteria
-
Patient is 18 to 75 years of age, inclusive.
-
Patient is skeletally mature.
-
Patient qualifies for primary unilateral or bilateral (simultaneous or staged) total hip arthroplasty (THA) based on physical exam and medical history including the following:
- Avascular necrosis (AVN)
- Osteoarthritis
- Inflammatory arthritis (i.e., Rheumatoid arthritis)
- Post-traumatic arthritis
-
Patient has no history of previous prosthetic replacement device of any type, including surface replacement arthroplasty, endoprosthesis, etc. of the affected hip joint(s).
-
Patient has moderate, marked or disabling pain.
-
Patient is willing and able to provide written informed consent.
-
Patient is willing and able to cooperate in the required post-operative therapy.
-
Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.
-
Patient has participated in the Informed Consent process and has signed the IRB approved informed consent.
Exclusion Criteria:
-
The patient is:
- A prisoner
- Mentally incompetent or unable to understand what participation in the study entails
- A known alcohol or drug abuser
- Anticipated to be non-compliant
-
The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure or complications in postoperative care.
-
The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.
-
The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.
-
The patient is known to be pregnant.
-
The patient is unwilling or unable to give consent or to comply with the follow-up program.
-
The patient has received an investigational drug or device within the previous 6 months.
-
The patient has an active or latent infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.
-
The patient has insufficient bone stock to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e., osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be used to assess the presence of adequate bone stock.
-
The patient has osteoradionecrosis in the affected hip joint.
-
The patient has a known sensitivity or allergic reaction to one or more of the implanted materials.
-
The patient has known local bone tumors and/or cysts in the operative hip.
-
The patient has a Body Mass Index (BMI) > 40.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Continuum Acetabular System
Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System |
Used in primary hip arthroplasty
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Survivorship
Ramy czasowe: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Based on removal or intended removal of the device and determined using the Kaplan-Meier method. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Safety / Adverse Events
Ramy czasowe: Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects. |
Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Pain and Function / HHS
Ramy czasowe: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Pain and function will be measured using the Harris Hip Score self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Pain and Function / OHS
Ramy czasowe: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Pain and function will be measured using the Oxford Hip Score self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Health Status / SF-12
Ramy czasowe: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Health status will be measured using the SF-12 self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Health Status / Radiographic Parameters
Ramy czasowe: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
X-rays will be evaluated for acetabular cup angle, acetabular cup migration, femoral stem position, femoral stem subsidence and femoral stem shift. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Metal Ion / Cobalt
Ramy czasowe: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Metal Ion / Chromium
Ramy czasowe: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Metal Ion / Titanium
Ramy czasowe: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / BUN
Ramy czasowe: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / Creatinine
Ramy czasowe: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / GFR
Ramy czasowe: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: Hillary Overholser, Zimmer Biomet
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Szacowany)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby kości
- Choroby układu mięśniowo-szkieletowego
- Procesy patologiczne
- Choroby stawów
- Choroby reumatyczne
- Choroby tkanki łącznej
- Choroby Autoimmunologiczne
- Choroby układu odpornościowego
- Martwica
- Stany patologiczne, oznaki i objawy
- Choroby skóry i tkanki łącznej
- Artretyzm
- Zapalenie kości i stawów
- Zapalenie stawów, reumatoidalne
- Martwica kości
- Procedury chirurgiczne, operacyjny
- Arthroplastyka, zastępca
- A arthroplasty
- Procedury ortopedyczne
- Procedury chirurgii plastycznej
- Implantacja protezy
- Arloplastyka, zamiennik, biodro
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- CMU2010-02H
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .